Tenaya Posts $18.9M Q3 Loss, Cash Through Q4 2027, Year-End Data on TN-201/TN-401
TNYA is trading near its 52-week low of $0.351 (9.7% above the low).
Summary
Tenaya reported a $18.9M Q3 loss with $66.8M in cash funding operations into Q4 2027, and said pivotal-trial regulatory feedback plus longer-term TN-201 and TN-401 data are due by year-end.
Key Events · Earnings and Guidance · TNYA
-
Q3 Loss Narrows to $18.9M
Net loss was $18.9M, or $0.08 per share, versus $20.3M ($0.12 per share) in Q3 2025; R&D fell to $14.9M from $15.4M and G&A held at $5.6M.
-
Cash Runway Into Q4 2027
Cash and equivalents stood at $66.8M as of September 30, 2026, down from $100.5M at December 31, 2025, with management guiding to funding into Q4 2027.
-
Year-End Data and FDA Feedback Due
One-year Cohort 2 and two-year Cohort 1 durability data for TN-201 and TN-401, plus regulatory feedback on pivotal trial planning, are all expected by year-end.
-
TN-301 Phase 2 Targeted for 2H 2027
Study-enabling work is underway, with at least one company-sponsored Phase 2 trial in patients planned for the second half of 2027.
Analysis · TNYA · Life Sciences
The quarter itself is unremarkable — the loss narrowed to $18.9M from $20.3M and spending is flat — but the balance sheet is the story. With $66.8M in cash and a stated runway into Q4 2027, Tenaya has roughly a year of funding before it must raise again, and it is doing so at a $0.385 share price with a reverse split already queued for a December 9 shareholder vote. Everything now hinges on the year-end readouts: one-year Cohort 2 and two-year Cohort 1 durability data for both TN-201 and TN-401, plus regulatory feedback on pivotal trial designs. Those results determine whether the company can fund late-stage development or must dilute heavily first.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNYA was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.3M. The 52-week trading range was $0.35 to $1.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.